Editas Medicine, Inc. (NASDAQ:EDIT) Q3 2023 Earnings Call Transcript November 3, 2023 Editas Medicine, Inc. beats earnings expectations. Reported EPS is $-0.00055, expectations were $-0.64. Operator: Good morning, and welcome to Editas Medicine’s Third Quarter Conference Call. All participants are now in listen-only mode. There will be a question-and-answer session at the end of this […]
Company to provide a clinical update on the EDIT-301 RUBY trial for SCD and EdiTHAL trial for TDT in December at the American Society of Hematology Annual Meeting and in a Company-sponsored webinar .
Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.